Active pharmaceutical ingredients parallel

To support product portfolio and multisite capacity planning under uncertainty for pharmaceutical plants Levis and Papageorgiou (2004) develop a two-stage stochastic MILP. The authors consider clinical trials outcomes and the customer demand as uncertain parameters. An MILP model that evaluates the profitability of introducing new active ingredients into the product pipeline for multiple parallel production lines in campaign mode is presented by Sundaramoorthy and Karimi (2004). 

---